Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
CITIC Securities: Sodium-ion batteries are expected to reach cost parity and large-scale production by 2027, and rising lithium carbonate prices are accelerating this process

CITIC Securities: Sodium-ion batteries are expected to reach cost parity and large-scale production by 2027, and rising lithium carbonate prices are accelerating this process

老虎证券老虎证券2026/04/21 23:41
Show original
We expect leading sodium battery manufacturers to achieve price parity with lithium batteries by the end of 2026, and that sodium batteries will enter an era of scaled parity deployment in 2027. Large-scale energy storage will be the main battlefield for the commercialization of sodium batteries, with overseas owners willing to pay a safety premium, leading to overseas energy storage stations scaling up first. In the medium term, sodium batteries are expected to gain a foothold in the power sector due to advantages such as low-temperature performance and enhanced safety. We estimate that market demand for sodium batteries could reach 500 GWh by 2030. It is important to seize the opportunity for the industrialization and scaling of sodium batteries, with priority given to areas such as battery production and aluminum foil segments.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks